



(12) Translation of
European patent specification

(11) NO/EP 3202461 B1

NORWAY

(19) NO
(51) Int Cl.
A61P 35/00 (2006.01)
C07D 401/12 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.05.13
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.12.26
(86)	European Application Nr.	17157178.9
(86)	European Filing Date	2011.02.10
(87)	The European Application's Publication Date	2017.08.09
(30)	Priority	2010.02.11, US, 303618 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA; ME
(62)	Divided application	EP2536706, 2011.02.10
(73)	Proprietor	Celgene Corporation, 86 Morris Avenue, Summit, NJ 07901, USA
(72)	Inventor	Man, Hon-Wah, 27 Grant Way, Princeton, NJ New Jersey 08540, USA Muller, George W., P.O. Box 3688, Rancho Santa Fe, CA California 92067, USA Ruchelman, Alexander L, 15 Cutter Court, Cream Ridge, NJ New Jersey 08514, USA KHALIL, Ehab M., 305 Glebe Spring Lane, Yorktown, VA Virginia 23693, USA Chen, Roger, Shen-Chu, 110 Christie St, Edison, NJ New Jersey 08820, USA ZHANG, Weihong, 831-d Donaldson Street, Highland Park, NJ New Jersey 08904, USA
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge


(54)	Title	ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME
------	-------	--

(56)	References Cited:	WO-A2-2008/115516 NAKAMURA TAKANORI ET AL: "Mono- and dihydroxylated metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 54, no. 12, 1 December 2006 (2006-12-01), pages 1709-1714, XP002628364, ISSN: 0009-2363, DOI: 10.1248/CPB.54.1709
------	-------------------	--

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse med formel (IV):



(IV)

eller et farmasøytisk akseptabelt salt, solvat eller stereoisomer derav, hvor:

X er N eller C;

Y er CH₂ eller C=O;

R¹¹ og R¹² hver uavhengig er hydrogen, -(C₁-C₆)alkyl, -(C₁-C₆)alkyl- (C₃-C₆)cykloalkyl, -(C₁-C₆)alkoksy, -(C₆-C₁₀)aryl, -CO(C₁-C₆)alkyl, -CO(C₃-C₆)cykloalkyl, -CO(C₆-C₁₀)aryl, -COO(C₁-C₆)alkyl, halogen, hydroksyl, okso, 3- til 10-leddet heterosyklisk gruppe, 6- til 10-leddet heteroaryl, -NHCO(C₁-C₆)alkyl, -(CH₂)_n-fenyl, -SO₂(C₁-C₆)alkyl, -SO₂(C₃-C₆)cykloalkyl, -SO₂(C₆-C₁₀)aryl eller -NR¹⁴R¹⁵, hvor alkyl-, aryl- eller heteroaryldelen av hver av gruppene eventuelt kan være substituert med ett eller flere halogen,

hydroksyl eller -(C₁-C₆)alkoksy;

R¹³ er hydrogen eller -(C₁-C₆)alkyl;



R¹⁴ og R¹⁵ er hver uavhengig hydrogen eller -(C₁-C₆)alkyl; og

n er 0, 1, 2 eller 3.







2. Forbindelse ifølge krav 1, hvor X er N.

3. Forbindelse ifølge krav 1, hvor Y er CH₂.





4. Forbindelse ifølge krav 1, som er:





2









5







10





3









5







10





4







5









10



5









5







10



6







5









10



7







5






10

8




5



eller et farmasøytisk akseptabelt salt, solvat eller stereoisomer derav.

10

5. Forbindelse ifølge krav 4, som er:



eller et farmasøytisk akseptabelt salt eller stereoisomer derav.

6. Farmasøytisk sammensetning omfattende en forbindelse ifølge hvilket som helst av kravene 1-4, eller et farmasøytisk akseptabelt salt, solvat eller stereoisomer derav.

5

7. Farmasøytisk sammensetning omfattende en forbindelse ifølge krav 5 eller et farmasøytisk akseptabelt salt eller stereoisomer derav.

10

8. Forbindelse ifølge hvilket som helst av kravene 1-4, eller et farmasøytisk akseptabelt salt, solvat eller stereoisomer derav, eller farmasøytisk sammensetning ifølge krav 6 for anvendelse i en fremgangsmåte for behandling, håndtering eller forebygging av en sykdom eller lidelse, hvor sykdommen eller lidelsen er kreft, en lidelse forbundet med angiogenese, smerte, makuladegenerasjon eller et relatert syndrom, en hudsykdom, en pulmonal lidelse, en asbestrelatert lidelse, en parasittisk sykdom, en immundefektforstyrrelse, en CNS-lidelse, CNS-skade, aterosklerose eller en relatert lidelse, dysfunksjonell søvn eller en relatert lidelse, en smittsom sykdom, hemoglobinopati eller en relatert lidelse, eller en TNF α -relatert lidelse.

15

20

9. Forbindelse ifølge krav 5, eller et farmasøytisk akseptabelt salt eller stereoisomer derav, eller farmasøytisk sammensetning ifølge krav 7, for anvendelse i en fremgangsmåte for behandling, håndtering eller forebygging av en sykdom eller lidelse, hvor sykdommen eller lidelsen er kreft, en lidelse forbundet med angiogenese, smerte, makuladegenerasjon eller et relatert syndrom, en hudsykdom, en pulmonal lidelse, en asbestrelatert lidelse, en parasittisk sykdom, en immundefektforstyrrelse, en CNS-lidelse, CNS-skade, aterosklerose eller en relatert lidelse, dysfunksjonell søvn eller en relatert lidelse, en smittsom sykdom, hemoglobinopati eller en relatert lidelse, eller en TNF α -relatert lidelse.

25